Q4 2023 Clover Health Investments Corp Earnings Call

Ladies and gentlemen, good afternoon, and welcome to the clever health fourth quarter and full year 2023 earnings conference call.

Operator: Ladies and gentlemen, good afternoon, and welcome to the Clover Health fourth quarter and full year 2023 earnings conference call. At this time, all participants are in a listen-only mode.

At this time all participants are in a listen only mode. A question and answer session will follow the prepared remarks at that time, if you wish to ask a question. Please press star one on your telephone keypad. As a reminder, today's call is being recorded I would now like to turn the call over to Ryan Smith Investor Relations for whoever else.

Operator: A question-and-answer session will follow. At that time, if you wish to ask a question, please press star 1 on your telephone keypad. As a reminder, today's call is being recorded. I would now like to turn the call over to Ryan Schmidt, Investor Relations for Clover Health. Please go ahead.

Go ahead Sir.

Good afternoon, everyone. Joining me on our call today to discuss the company's fourth quarter and full year 2023 results are Andrew Toy Overhauls, Chief Executive Officer, and Terry Ronan The company's interim Chief Financial Officer, you can find today's press release and the accompanying supplemental slides in the investor events and presentations.

Ryan Schmidt: Good afternoon, everyone. Joining me on our call today to discuss the company's fourth quarter and full year 2023 results are Andrew Toy, Clover Health's Chief Executive Officer, and Terry Ronan, the company's Interim Chief Financial Officer. You can find today's press release and the accompanying supplemental slides in the Investor Events and Presentations section of our website at investors.cloverhealth.com. This webcast is being recorded, and a replay will be available in the Investor Relations section of Clover Health's website. I'd also like to caution you that we may make forward-looking statements during today's call that are subject to risks and uncertainties, including expectations about future performance. Factors that may cause actual results to differ materially from expectations are detailed in our SEC filings, including in the Risk Factors section of our most recent annual report on Form 10-K and other SEC filings. Information about the non-GAAP financial measures referenced, including a reconciliation of those measures to GAAP measures, can be found in the earnings materials available on our website. With that, I'll now turn the call over to Anne.

Section of our website.

Passengers that Clover House dotcom.

The webcast is being recorded and a replay will be available in the Investor Relations section of the corporate website.

I'd also like to caution you that we may make forward looking statements. During today's call are subject to risks and uncertainties, including expectations about future performance factors that may cause actual results to differ materially from expectations are detailed in our SEC filings, including in the risk factors section of our most recent annual report on Form 10-K and other.

Our SEC filings information about non-GAAP financial measures referenced including a reconciliation of those measures to GAAP measures can be found in the earnings materials are available on our website with that I'll now turn the call over to Andrew.

Thank you Ryan.

Andrew Toy: Thank you, Ryan. I'm very excited to be putting the finishing touches on a very strong year of execution for Clover. We've delivered a step-change improvement in our financial performance in the same year that the greater Medicare Advantage ecosystem took a step back, which I feel proves the power of our technology-centric model. We are aiming to deliver a profitable, adjusted EBITDA year in 2024 while continuing to invest heavily in our core technology asset, Clover Assist. We will then be in a position to return to growth during a period where we anticipate our competitors will be retreating and will aim to continually build on the strategic lead we have developed. With that in mind, let's now walk through our 2023 performance.

Very excited to be putting the finishing touches on a very strong year of execution for silver.

We have delivered a step change improvement in our financial performance in the same year that the greater Medicare advantage ecosystem took a step back which I feel proves out the power of our technology centric model.

We are aiming to deliver a profitable adjusted EBITDA year in 2024, while continuing to invest heavily in our core technology assets Clover assistance. We will then be in a position to return to growth during a period, where we anticipate our competitors will be retreating I will aim to continually build on the strategic lead we have.

Pellets.

With that let's now walk through our 2023 performance.

Beginning with our insurance results, we delivered in M. C are up 82, 4% in the fourth quarter of 2023, bringing our full year MCR performance to 81, 2%.

Andrew Toy: Beginning with our insurance results, we delivered an MCR of 82.4% in the fourth quarter of 2023, bringing our full-year MCR performance to 81.2%. This outcome maintains Clover's trend of significant year-over-year MCR improvement since 2021. I want to emphasize that I'm not referring to a couple of percentage points of improvement.

This outcome maintained <unk> trend of significant year over year MCR improvement since 2021.

I want to emphasize that I'm not referring to a couple of percentage points improvements in two years, we've successfully reduced our insurance MCR by approximately 25 percentage points in 2021, our insurance MCR was 106% followed by Nike one 8% in 2020.

Andrew Toy: In two years, we've successfully reduced our insurance MCR by approximately 25 percentage points. In 2021, our insurance MCR was 106%, followed by 91.8% in 2022, and then most recently, 81.2% in 2023. The significant improvement in MCR since 2022 alone has driven a 181% improvement in our per member per month insurance gross profit, which has increased from an $87 PMPM profit in 2022 to a $245 PMPM profit in 2023. Most importantly, this step change improvement in our insurance results has translated to a full year 2023 adjusted EBITDA loss of $45 million, which is another significant improvement from 2022's loss of $290 million. I believe that this large improvement in gross profit and adjusted EBITDA demonstrates the rapid and outstanding progress we've made in our core business and is the result of clear focus by the Clover team.

And then most recently 81 point to 2% in 2023.

The significant improvement in M. C. R. Since 2022 alone has driven 181% improvement in our per member per month insurance gross profit, which has increased from $87 P. M. P. A profit in 2022 to a 245 dollar P. M. P M profit in 2023.

Right.

Most importantly, this step change improvement in our insurance results has translated to a full year 2023, adjusted EBITDA loss of $45 million, which is another significant improvement from 2020 two's loss of $290 billion.

I believe that this large improvement in gross profit and adjusted EBITDA demonstrates the rapid and outstanding progress we've made to our core business and is the result of clear focus by the <unk> team.

Andrew Toy: Over the past two years, we have focused on maturing operations, including improving processes to increase the accuracy of claims payment and the accuracy of risk adjustment. We have also focused on significantly increasing value delivered through our care management platform, underpinned by Clover Assistant and Clover Home Care, which helps us deliver proactive care management at scale and bends the cost curve for our sickest members. What's most important to me is that these impressive insurance results were generated within the context of a benefit-rich, wide network, PPO-first approach. We believe that this is the future of Medicare Advantage. Many in the industry have spent decades constructing their operations to manage utilization and financial performance within a narrow network HMO context. While this strategy was historically successful, we now see that the landscape is shifting rapidly. In fact, TPOs have grown at over two times the rate of these tightly controlled HMOs over the past five years, and this is a clear reflection of consumer preference for choice.

Over the past two years, we have focused on maturing operations, including improving processes to increase the accuracy of claims payments and the accuracy of risk adjustment.

We are also focused on significantly increasing value delivered through our care management platform underpinned by Clover assistant at Kluver, Homecare, which helps us deliver proactive care management at scale and bend the cost curve for our sickest members.

What's most important in my mind is that these impressive insurance results were generated within the context of a benefit rich widen network P. P. O first approach. We believe that this is the future of Medicare advantage.

Many in the industry have spent decades constructing their operations to manage utilization and financial performance within a narrow network HMO context. While this strategy was historically successful we now see that the landscape is shifting rapidly.

In fact ppos have grown at over two times the rate of these tightly controlled hmos over the past five years. This is a clear reflection of consumer preference for choice.

Andrew Toy: As industry-wide PPO penetration continues to expand from its current 43% and closer to the Clover PPO rate of 95%, we expect, and already see, that our peers will be confronted with increasing difficulty in managing their PPOs, especially since HMO and PPO frameworks are not easily interchangeable. On the other hand, we have built Clover to thrive in what we expect to be the future of the Medicare Advantage program. The investments we've made to build our care management platform and to empower more physicians with Clover-assisted technology have uniquely positioned us to deliver strong clinical and financial results within a PPO, as our 2023 results show. Ultimately, we believe that we are the only Medicare Advantage plan with a wide network care management model that's centered on technology-empowered physicians, and this will lead to a sustainable growth advantage over our competitors.

As industry wide keep your penetration continues to expand from its current 43% and closer to the <unk> P. P. O rate of 19, 5%, we expect and already see that our peers will be confronted with increasing difficulty in managing their TPS, especially since HMO and PPO frameworks are not easily interchangeable.

On the other hand, we have built kluver to thrive in what we expect to be the future of the Medicare advantage program.

The investments we've made to build our care management platform to empower more physicians with clearer assisted technology have uniquely positioned us to deliver strong clinical and financial results within a P. P. L. As our 2023 results show.

Ultimately, we believe that we are the only Medicare advantage plan with a wide network care management model, that's centered on technology empowered physicians and this will lead to a sustainable growth advantage over our competitors.

Another industry dynamic that I would like to discuss is the high variance in Medicare advantage utilization trends that have recently been in the public spotlight.

Andrew Toy: Another industry dynamic that I would like to discuss is the high variance in Medicare Advantage utilization trends that have recently been in the public spotlight. Going back to the first quarter of 2023, we did experience elevated trends year over year that continue to persist through year end. That said, this was not unexpected in terms of our modeling for the year, particularly given year-over-year changes in member names.

Going back to the first quarter of 2023 we did experience elevated trends year over year that continue to persist through year end that said this was not unexpected in terms of our modeling for the year, particularly given year over year changes in member banks to be clear we did not.

Andrew Toy: To be clear, we did not see anything that we were not prepared for in terms of utilization trends during Q4, and I believe that our care management platform provides us with a unique ability to navigate any underlying shifts in industry trends. That all said, we do, of course, recognize that trend variances across Medicare Advantage were much wider than usual in Q4 and in other plans 2024 out. As such, we have layered an additional buffer in our reserving and 2024 forecast. For the full year 2024, we will be using a similar approach to guidance as we did last year, where we will aim to solidly improve upon our outlook throughout the year. We therefore are guiding to the following. Revenue for the insurance line of business to be between $1.25 billion and $1.3 billion, insurance MCR to be within a range of 79% to 83%, and adjusted SG&A to be between $270 million and $280 million.

See anything that we were not prepared for in terms of utilization trends during Q4, and I believe that our care management platform provides us with a unique ability to navigate any underlying shifts in industry trends.

That all said, we do of course recognize that trend variances across Medicare advantage were much wider than usual in Q4 and in other plans 'twenty 'twenty four outlook as such we have layered in additional buffer in our reserving and 'twenty 'twenty four forecasting.

For the full year 2024, we will be using a similar approach to guidance as we did last year, where we will aim to solidly improved upon our outlook throughout the year.

We therefore are guiding to the following.

Revenue for the insurance line of business to be between 1.25 billion and $1.3 billion.

Insurance MCR to be within a range of 79% to 83%.

Adjusted SG&A to be between $270 million and $280 million.

Andrew Toy: Lastly, we expect these favorable improvements to result in a full year 2024 adjusted EBITDA range of negative $20 million to positive $20 million, representing an improvement of approximately $45 million year-over-year at the breakeven midpoint and a $65 million improvement at the top end of our range. We believe that we are well positioned to deliver upon our initial outlook, even as we have priced in headwinds that may be coming from broader industry utilization trends into this guidance. But another way, if those trends do not develop, I believe we are well placed to achieve the high end of our range. Putting industry trends aside, we have significant momentum from the continued focused efforts that we have been executing on in the last two years, which will help us deliver profitable adjusted EBITDA in 2024.

Lastly, we expect these favorable improvements to result in a full year 2024, adjusted EBITDA range of negative 20 million to positive $20 million, representing an improvement of approximately $45 million year over year at the break even the midpoint at a $65 million improvement.

At the top end of our rich.

We believe that we are well positioned to deliver upon our initial outlook, even as we have priced in headwinds that may be coming from broader industry utilization trends into this guidance.

Put another way if those trends do not develop I believe we are well placed to achieve the high end of our range.

Putting industry trends aside we have significant momentum from the continued focused efforts that we have been executing on in the last two years, which will help us deliver profitable adjusted EBITDA in 2024.

Andrew Toy: This momentum includes continued R&D into Clover Assistant throughout 2023, where we expect to see impact in 2024. We also have strong Clover Home Care coverage in 2023, which we expect to benefit our MedEx control throughout 2023. On the SG&A front, we are currently executing upon our previously discussed transformation to refine and replatform insurance operations, where we disclosed last year that we would expect material savings to be enjoyed in 2024. Lastly, our 2024 AEP strategy once again focused on margin for market retention and revenue topline.

This momentum includes continued RMB into clearer assisted throughout 2023, where we expect to see impact in 2024.

We also had strong clover home care coverage in 2023, which we expect to benefit our medics control throughout 2024.

On the SG&A front, we are currently executing upon our previously discussed transformation to refine and re platform insurance operations, where we disclosed last year that we would expect material savings to be enjoyed in 2024.

Lastly, our 2020 for AEP strategy once again focused on margin core market retention and revenue topline.

Andrew Toy: Given this, we feel good about our member levels at NICS, as well as our ability to achieve our 2024 profitability goal. Overall, our 2023 results represent another important milestone on our path to profitability. We believe that we are well positioned to achieve the goals we've laid out for 2024 without the need for additional capital.

Given this we feel good about our member levels at mix as well as our ability to achieve our 2024 our profitability goals.

Overall, our 2023 results represent another important milestone on our path to profitability. We believe that we are well positioned to achieve the goals, we laid out for 'twenty 'twenty four without the need for additional capital.

Adam Matan Ron: As our business continues to mature, we strongly believe that the moat afforded by Clover Assistant and Clover Home Care, coupled with our focus and investments to improve our star's performance, will allow us to expand our positioning from steady profitability to highly profitable growth. With that, I'll now hand it to Terry for the more detailed financial update. Thanks, Andrew.

As our business continues to mature we strongly believe that the boat afforded by Clover assistant and Clover homecare, coupled with our focus and investments to improve our stars performance will allow us to expand our positioning from steady profitability two highly profitable growth.

With that I'll now hand, it to Terry with a more detailed financial update.

Thanks, Andrew Clover Health delivered an adjusted EBITDA loss of $19 million during Q4, and a loss of $45 million for the <unk>.

Adam Matan Ron: Clover Health delivered an adjusted EBITDA loss of $19 million during Q4 and a loss of $45 million for the full year, both a significant improvement over the prior period losses of $80 million and $290 million in 2022, respectively. As a reminder, at this time last year, we provided initial 2023 full-year adjusted EBITDA guidance of negative $180 million at the midpoint. We came in favorable to this initial guidance by $135 million and are obviously pleased with this result, as well as the momentum this brings into 2024. For the insurance segment, MCR improved to 82.4% in Q4 from 92.4% in Q4 of last year. For the full year, Insurance MCR improved by more than 10%, from 91.8% in 2022 to 81.2% in 2023. Our strong MCR was paired with continued revenue growth of 12% and 14% to $303 million and $1.2 billion. Q4 from the full year 2023 respectively.

Full year with a significant improvement over the prior period losses of $80 million and $290 million in 2022, respectively.

As a reminder, at this time last year, we provided initial 2023 full year adjusted EBITDA guidance of negative $180 million at the midpoint.

We came in favorable to this initial guidance by $135 million and obviously pleased with this result, as well as the momentum springs into 2024.

But the insurance segment.

See our improved to 82, 4% in Q4 from 92, 4% in Q4 of last year.

Full year insurance NCR improved by more than 10 percentage points from 91, 8% in 2020 to 81, 2% in 2023.

Our strong M. C. I was tagged with continued revenue growth of 12% and 14% to $303 million at $1.2 billion.

Our Q4 and the full year 2023, respectively.

We continue to realize favorable impacts from various operating initiatives during the year and we believe our full year MCR a good representation of the underlying performance of the business.

Our non insurance MTR during the fourth quarter was 102% as compared to Q4 of 2022 MCR of 103, 6%.

Full year 2023, non insurance MCR.

Adam Matan Ron: We continue to realize favorable impacts from various operating initiatives during the year, and we believe our full-year MCR is a good representation of the underlying performance of the business. Our non-insurance MCR during the fourth quarter was 100.2% as compared to Q4 2022 MCR of 103.6%. Full year 2023 non-insurance MCR of 99.8% was a better result compared to our MCR of 103.4% in 2020. Our Q4 and full year 2023 non-insurance segment revenue each declined 68% versus the prior year periods, respectively, to $198 million in Q4 and $773 million for the full year. As a reminder, the company exited the ACO REACH program at the end of the 2023 performance year to focus more effort and resources on its core Medicare Advantage offering. Fourth quarter adjusted SG&A was $81 million, down 4% year-over-year.

99, 8%.

It was a better result, compared to our MCR at 103, 4% in 2022.

Our Q4 and full year 2023, non insurance segment revenue each declined 68% versus the prior year periods, respectively to $198 million in Q4 and $773 million for the full year.

As a reminder, the company exited the ACL reach program at the end of the 2023 performance year focus more effort and resources on its core Medicare advantage offerings.

Fourth quarter, adjusted SG&A was $81 million down 4% year over year on a full year basis. The company reduced adjusted SG&A from $312 million in 2000 $22 million to $302 million in 2023, representing cost savings of 3% since last year.

Sure.

In January we successfully transitioned over to our new MA plan operational ecosystem.

We expect will provide us with a stable back office functions and the opportunity for greater economies of scale bigger.

Beginning in 2020 for this transition creates both financial cost savings for Clover beyond our 2023 performance and also allows the team to focus more specifically on what we believe to be our competitive advantages.

Adam Matan Ron: On a four-year basis, the company reduced adjusted SG&A from $312 million in 2022 to $302 million in 2023, representing cost savings of 3% since last year. In January, we successfully transitioned over to our new MA Plan operational ecosystem, which we expect will provide us with stable back office functions and the opportunity for greater economies of scale. Beginning in 2024, this transition creates both financial cost savings for Clover beyond our 2023 performance and also allows the team to focus more specifically on what we believe to be our competitive advantage. Turning to the balance sheet, we finished 2023 with restricted and unrestricted cash, cash equivalents, and investments totaling $417 million on a consolidated basis, with $137 million at the parent entity and unregulated subsidiary level. This result is in line with our expectations for year-end cash and as a result of various impacts that the company has discussed in the past. Last quarter, we received both the September and October M.A.

Turning to the balance sheet, we finished 2023 with restricted and unrestricted cash cash equivalents and investments totaling $417 million on a consolidated basis.

$137 million at the parent entity and unreliable unregulated subsidiary level.

This result is in line with our expectations for year end cash and as a result of various impacts that the company has discussed in the past.

Last quarter, we received both the September and October MA payments from CMS during the month of September which happened to every MAA payer temporarily.

<unk>, our Q3 cash by $103 million, the regulated entity and consolidated level.

As expected this working capital effect normalized in Q4.

In addition, consolidated unregulated balances were also impacted by.

The expected Q4 $147 million cash payment to CMS for the final settlement of the 2022 performance year related to our ACO reach participation.

Overall, we believe that our current liquidity position is strong without the need for any additional capital this year.

Having said that like any company, we do continue to consider opportunistic financings to increase liquidity.

Adam Matan Ron: payments from CMS during the month of September, which happened to every MA payer, temporarily elevating our Q3 cash by $103 million at the regulated entity and consolidated level. As expected, this working capital effect normalized in Q4. In addition, consolidated and unregulated balances were also impacted by the expected Q4 $147 million cash payment to CMS for the final settlement of the 2022 performance year related to our ACO REACH participation.

You can expect us to continue to prudently manage our strong liquidity position as we work to achieve 2020 for profitability on an adjusted EBITDA basis.

In summary, Clover delivered impressive progress on its path to profitability. This year the significant year over year improvement in its key operating metrics.

Now I'll turn the call back to Andrew for some closing comments.

Thanks Terry.

I hope that our comments today further portray our confidence to deliver upon our 2024 targets.

For opening it up for Q&A I'd like to close with my thoughts on the state of our unique care management platform, which consists of differentiated AI powered technology with clearer assistant asset light wrap around care services with Kluver homecare.

Andrew Toy: Overall, we believe that our current liquidity position is strong without the need for any additional capital this year. However, having said that, like any company, we do continue to consider opportunistic financings to increase liquidity. You can expect us to continue to prudently manage our strong liquidity position as we work to achieve 2024 profitability on an adjusted EBITDA basis. In summary, Clover delivered impressive progress on its path to profitability this year, with significant year-over-year improvement in its key operating metric. Now I'll turn the call back to Andrew for some closing comments. Thanks, Terry.

We see these as entirely synergistic capabilities.

We aim to care for all of our membership with see a powered positions in our wide network.

If these members need extra support and care coordination any kluver member can have a no cost C. A powered visit from <unk> home care in the comfort of their own home.

For the most vulnerable and therefore highest utilizing members kluver homecare deployed a fully accountable primary and palliative care program called in Homecare. These programs are achieving meaningful scale and results.

Going a little deeper on the technology platform side, you May have heard me say before that we are not building in short tech that is we're not building software to improve the administrative functions of insurance, rather we are building software to improve clinical care.

Andrew Toy: I hope that our comments today further portray our confidence to deliver upon our 2024 targets. Before opening it up for Q&A, I'd like to close with my thoughts on the state of our unique care management platform, which consists of differentiated AI power technology with Clover Assistant and asset-light wraparound care services with Clover Home Care. We see these as entirely synergistic capabilities. We aim to care for all of our membership with CA-powered physicians in our wide network. If these members need extra support and care coordination, any Clover member can have a no-cost computer-powered visit from Clover Home Care in the comfort of their own home.

We've shared in the past that returning members, who see a kluver assistant provider, a far lower mcr's than dose, who see a non clover assistant provider.

Over the last few years, we've continually made investments into the C. A platform.

Every day, we continue to expand upon our vastly differentiated data retrieval capabilities using our superior AI native platform to process that data rapidly and leveraging our C. A network to deploy those insights to positions to maintain the closed loop.

We expect these meaningful advancements in clover assistance capabilities to continually improve the impact that our technology has on our business performance and more importantly continually improve the care that our members receive.

Andrew Toy: For the most vulnerable and therefore highest-utilizing members, Clover Home Care deploys a fully accountable primary and palliative care program called In-Home Care. These programs are achieving meaningful scale and results. Going a little deeper on the technology platform side, you may have heard me say before that we are not building InsurTech. That is, we're not building software to improve the administrative functions of insurance.

Switching to Kluver homecare in 2023, approximately 5% of our members were enrolled in our in home care primary care practice, where we manage our highest risk and highest need members.

This high touch program was able to produce approximately $500 in net P. M. P. M medical expense savings driven by lower spend at the end of life and reduced inpatient admissions.

Andrew Toy: Rather, we are building software to improve clinical care. We've shared in the past that returning members who see a Clover Assistant Provider have far lower MCRs than those who see a non-Clover Assistant Provider. Over the last few years, we've continually made investments in the CA platform. Every day, we continue to expand upon our vastly differentiated data retrieval capabilities using our superior AI-native platform to process that data rapidly and leveraging our CA network to deploy those insights to positions to maintain the closed loop. We expect these meaningful advancements in Clover assistance capabilities to continually improve the impact that our technology has on our business performance and, more importantly, continually improve the care that our members receive. Switching to Clover Home Care, in 2023, approximately 5% of our members were enrolled in our in-home care primary care practice, where we manage our highest risk and highest need members. This high-touch program was able to produce approximately $500 in net PMPM medical expense savings, driven by lower spend at the end of life and reduced inpatient admissions. Beyond primary care, Clover Home Care also provides services to approximately 23% of our population via a portfolio of programs that are also primarily home-based and Clover Assistant driven.

Beyond primary care Kluver Homecare also provides services to approximately 23% of our population via a portfolio of programs that are also primarily home based and Clover assisted driven.

These programs focus on advanced illness.

Preventive wellness readmission reduction and behavioral health.

As an example of the efficacy of these programs, where we examine our data we see a reduction of inpatient readmissions of approximately 25% in our readmission prevention program.

Bringing this all together we aim to have as much of our population as possible have access to clover assistant powered care.

Between our network primary care providers are employed primary care providers and our broader kluver homecare efforts. Our software platform was engaged in caring for over two thirds of our population in 2023.

As you see the foundation of Clover assistant and Clover homecare uniquely positions us to managed care in the PPO context, we're delighted by the continued progress of Clover assistant and clever health care and they're increasing impact on our results.

Our expectation is that both of these assets will continue to pay dividends I see ROI expansion over the coming years.

In summary, we are obviously proud of our results and the momentum we have built in 2023.

Within our P. P. O first framework Kluver operates with both member choice and access to care at the key pillars of our offering.

Our tech enabled platform allows our insurance segment to offer both amazing benefits and access as well as proactive care delivery to those who need it the most all while delivering strong financial results.

The fact that our entire clinical management model is driven by technology is something that we believe to be a significant vote for us and something that we think bodes well for the business as we move into an AI accelerated world.

Andrew Toy: These programs focus on advanced illness, preventative wellness, readmission reduction, and behavioral health. As an example of the efficacy of these programs, when we examine our data, we see a reduction of inpatient readmissions of approximately 25% in our readmission prevention program. Bringing this all together, we aim to have as much of our population as possible have access to Clover-assisted, powered care. Between our network primary care providers, our employed primary care providers, and our broader Clover home care efforts, our software platform was engaged in caring for over two-thirds of our population in 2023. As you can see, the foundation of Clover Assistant and Clover Home Care uniquely positions us to manage care in a PPO context.

With that let's move onto Q&A.

We will now be taking your questions, we will be taking questions from climate research analysts at this time, if you wish to ask a question. Please press star one on your telephone keypad, you may remove yourself from the queue by pressing star two and the interest of time, we ask that you. Please limit yourself to one question and one quick follow up.

Our first question comes from Jason Cazorla with Citi.

Great. Thanks, good afternoon, and congrats on the quarter just as it relates to the 1.25 to $1 3 billion of 'twenty 'twenty four revenue and guidance can you give us a sense on what expectations are between MAA enrollment declines and perhaps the offsetting P. M. P. M growth that's embedded in that call. It three person.

Andrew Toy: We're delighted by the continued progress of Clover Assistance and Clover Home Care and their increasing impact on our results. Our expectation is that both of these assets will continue to pay dividends and see ROI expansion over the coming years. In summary, we are obviously proud of our results and the momentum we have built in 2023. Within our PPO First framework, Clover operates with both member choice and access to care as the key pillars of our offering.

Top line growth at the midpoint.

Yeah, Hey, Jason So the way that we're looking at this as we said in the remarks is that we have been pricing the plan and the product I think very appropriately and so we expect to see Appian Pam improvements, mainly due to the effect of member mix and returning member mix. So while we are managing to plan to.

A little bit flatten a little bit down growth is not our main focus right now we do expect to see significant continued improvements through plant operations and through member mix, where we would see that P. M. P. M revenue increase and therefore, that's what would drive that revenue number.

Operator: Our tech-enabled platform allows our insurance segment to offer both amazing benefits and access, as well as proactive care delivery to those who need it the most, all while delivering strong financial results. The fact that our entire clinical management model is driven by technology is something that we believe to be a significant moat for us and something that we think bodes well for the business as we move into an AI-accelerated world. With that said, let's move on to Q&A. We will now be taking questions from Clover's research analysts. At this time, if you wish to ask a question, please press star 1 on your telephone keypad. You may remove yourself from the queue by pressing star 2.

Okay, so predominantly driving <unk> P. M. P M got got it okay.

And then just my quick follow up here is the cash generation just as we think about the $137 million of unregulated cash at the end of the year.

Should we think about that breakeven EBITDA expectation as a proxy for cash flow from ops in 'twenty four and then can you give us a sense on what the potential cash outflow would look like from any settlement sure up with CMS given your full ACL reach business exit, including the incremental working capital unwind that may happen, because we've completely exited the business at this point. Thanks.

Operator: In the interest of time, we ask that you please limit yourself to one question and one quick follow-up. Our first question comes from Jason Cassorla with Citi. Great, thanks. Good afternoon, and congratulations on the quarter.

Yeah. So a couple of different questions you had data great ones I think there's a couple of different things number one is as we look at the unregulated number I would note that there are a lot of our profitability being that caches inside the regulated entity right now and we have some operational methodologies, where cash would move between those two entities with partial.

Andrew Toy: Just as it relates to the $1.25 to $1.3 billion of 2024 revenue and guidance, can you give us a sense of what expectations are between MA enrollment declines and perhaps the offsetting PM-PM growth that's embedded in that, call it 3% top-line growth at the midpoint? Yeah. Hey, Jason.

Offsetting any outflow from the unregulated so we feel pretty good about our unregulated cash position regarding ACO, we have been reducing we did exit last year as everyone knows and we have been lowering our exposure. So it's a it's a reduced exposure that we had even in 2023, which is the last year of participation in the program. So.

Andrew Toy: So, the way that we're looking at this, as we said in the remarks, is that we have been pricing the plan and the product, I think, very appropriately. And so, we expect to see PMPM improvements mainly due to the effect of member mix and returning member mix. So, while we are managing the plan to be a little bit flat and a little bit down, growth is not our main focus right now. We do expect to see significant continued improvements through plan operations and through member mix, where we would see that PMPM revenue increase. And therefore, that's what would drive that revenue number. Okay, so predominantly driving to the p.m. p.m. growth. I got it.

We priced all of that into our modeling for the cash flow position and we feel good about our unregulated cash we feel good about where we sit on the overall liquidity and as we said our current go off management is to target adjusted EBITDA profitability. This year without the need for any additional capital in the unregulated entity.

Great. Thanks, and maybe if I could just follow up one last question.

I guess first can you give us a sense on how you approached 25 beds and then just a follow on to that you know and understanding that you recognize MLR improvements over time when a member is attributed to the call of our assistant right I guess, given the higher pricing you've established your plans over the past couple of years, the 20% P. M revenue P. M. P M growth in 'twenty three.

Adam Matan Ron: Okay. And then just my quick follow-up here is the cash generation, just as we think about 137 million of them are really cash at the end of the year, you know, should we think about that breakeven EBITDA expectation as a proxy for cash flow from operations in 24? And then can you give us a sense of what the potential cash outflow would look like from any settlement true up with CMS given your full ACO reach business exit, just including the incremental working capital unwind that may happen because he's completely exited the business at this point? Yeah, so a couple of different questions you had there, great ones. I think there are a couple of different things.

Growth in 24 can you just give us a sense on how to think about what the profitability of a new member to Cobra looks like today I'm, especially when you do decide to flip to more membership growth aspiration.

Oh, yeah, sorry about that.

Great follow on question, Jason I can't do it full justice here, but the way that we think about it in a couple of different ways.

On that last part we do look carefully at our LTV CAC equation here and there's a couple of different dimensions, given that we do expect our publicly stated by other plans that they will be pulling back and re pricing their products. We really do think that there's an opportunity for us to leverage the fact that art.

Adam Matan Ron: Number one is, as we look at that unregulated number, I would note that a lot of our profitability means that cash is inside the regulated entity right now, and we have some operational methodologies where cash would move between those two entities, partially offsetting any outflow from the unregulated. So we feel pretty good about our unregulated cash position. Regarding ACO, we have been reducing our exposure; we did exit last year, as everyone knows, and we have been lowering our exposure. So it's a reduced exposure that we have even in 2023, which is the last year of participation in the program.

Technology, driven approach manages our membership much better than others, we believe and what that means is is that we don't necessarily have to improve or increase the richness of our plans as others pull back and we will enjoy a decrease in the overall customer acquisition cost. The other dimension is and we are we will be sharing more information.

Later on about the effect of Clover assistant on that LTV CAC equation, but I think it's a very interesting lever that we get that because we drive care through C. A by pulling up they'll see a visit and getting people see a visits earlier, we're able to also drive new are clues that LTV CAC equation and get the profitability on our members.

Adam Matan Ron: So we priced all of that into our modeling for the cash flow position, and we feel good about our unregulated cash. We feel good about where we sit on the overall liquidity. And as we said, our current goal as management is to target just EBITDA profitability this year without the need for any additional capital in the unregulated entity. Great, thanks. And maybe I can just follow up on one last question.

Sooner rather than later, we haven't shared that breakeven point, yet, but it's something that we might share in the future.

Just a reminder to ask a question. Please press star one.

Our next question comes from Richard close with Canaccord Genuity.

Andrew Toy: You know, I guess first, can you give us a sense of how you approach 25 bids, and then just to follow on to that, you know, and understand that you recognize MLR improvements over time when a member is attributed to the Clover Assistant, right? I guess, given the higher pricing you've established in your plans over the past couple of years, the 20% PM revenue, PM, PM growth in 23, and the likely growth in 24, can you just give us a sense of how to think about what the profitability of a new member to Clover looks like today, especially when you do decide to flip to more membership growth aspirations? Thanks. Yeah, so that's a great follow-on question, Jason. I can't do it full justice here, but the way that we think about it in a couple of different ways, on that last part. We do look carefully at our LTV CAC equation here, and there are a couple of different dimensions.

Yes, thanks, congratulations on the success in 2003 Andrew.

Andrew maybe talk a little bit more about the higher utilization that you baked into 2024.

Any more specifics that you can provide and just how to think about the low end and the high end of the range would be helpful.

Yes, I appreciate that.

Yeah, absolutely. So what we've done here just to be clear is that we feel very good about that momentum and we feel very good about the improvement in the business, we do see.

That others have seen this variability as I said in my remarks and to be clear we are not seeing any utilization that we did not anticipate so all we do have higher utilization, but we did anticipate that throughout 'twenty three we.

Andrew Toy: Given that we do expect, publicly stated by other plans, that they will be pulling back and repricing their products, we really do think that there's an opportunity for us to leverage the fact that our technology-driven approach manages our membership much better than others. And what that means is that we don't necessarily have to improve or increase the richness of our plans as others pull back, and we will enjoy a decrease in overall customer acquisition costs. The other dimension is, and we will be sharing more information later on about the effect of Clover Assistant on that LTV CAC equation, but I think it's a very interesting lever that we get because because we drive care through CA, by pulling up those CA visits and getting people to have those CA visits earlier, we're able to also close that LTV CAC equation and get the profitability on a member sooner rather than later. We haven't shared that breakeven point yet, but it's something that we might share in the future. Just a reminder, to ask a question, please press star 1. Our next question comes from Richard Close with Canaccord News. Yeah, thanks. Congratulations on your success in 23.

In the quarter for Q4, nothing that we didn't no surprises effectively so what we did when we looked at our guide for us.

Outside of Q4, but when we look at our guide for full year 2024.

Is to say look we feel pretty good that we could target and we would land potentially near the higher end of that range that we provided so we guided to you <expletive> 'twenty to 'twenty, we looked and said we could come near the higher end of that range as I said in my remarks, but then we said we wanted to increase the width of that range because there may be.

Unexpected effects systemic to the environment that others are seeing that maybe haven't hit us yet we aren't saying that we are seeing that we are saying that we are being prudent in managing that guidance range as we sort of have Q1 Q2 and the year develops as we have claims run out we expect to narrow that range and hopefully provide tighter guidance on where we end up and again hopefully.

We will have priced in everything appropriately and we will see ourselves come in on the higher end.

Okay, that's helpful and.

How are you thinking about star ratings and improving that going forward.

Yeah, absolutely and so one thing that I will say is that we are focused on our star rating and making sure that we are able to clearly land and execute against the three five star rating and then have a pathway to for a couple of different things that we are able to say about our performance.

Andrew Toy: Andrew, maybe talk a little bit more about the higher utilization that you baked into 2024, any more specifics that you can provide, and just how to think about the low end and the high end of the range would be helpful. Yeah, absolutely. So what we've done here, just to be clearer, is that we feel very good about the momentum, and we feel very good about the improvement in the business. We do see that others have seen this variability, as I said in my remarks, and to be clear, we are not seeing any utilization that we did not anticipate. So all, we do have higher utilization, but we did anticipate that throughout 23. We had in the quarter for Q4, nothing that we didn't, effectively. So what we did when we looked at our guide for outside of Q4, but when we looked at our guide for full year 2024, is to say, look, we feel pretty good that we could target and we would land potentially near the higher end of that range that we provided. So we got it to negative 20 to 20.

There number one is that with the two key methodology being applied last year. One thing that did come into play is these new guard rails around star ratings, what that does is while the baseline for Starz did shifts significantly last year. There is also significantly more predictability now and were cut.

Since we will land and I think that is advantageous to not just us, but all plans in terms of having higher predictability and that's something where pricing into all of our star rating methodologies. So that we know that we can manage against that three and a half stars and then proceed nicely towards that far four star level second of all I do think that when we look at star.

Ratings it much harder to predict your star rating when Youre growing significantly and both in 'twenty three and 24, we have a more stable membership and because of that more stable membership, we're able to anticipate things like star rating performance the things like our med adherence denominators are more stable and we are also able to estimate.

Andrew Toy: We looked and said we could come near the higher end of that range, as I said in my remarks, but then we said we wanted to increase the width of that range because there may be unexpected effects systemic to the environment that others are seeing that maybe haven't hit us yet. We aren't saying that we are seeing that; we are saying that we are being prudent in managing that guidance range as we sort of have Q1, Q2, and the year develops as we have claims run out. We expect to narrow that range and, hopefully, provide tighter guidance on where we end up. And again, hopefully, we will have priced and everything appropriately, and we will see ourselves come in on the higher end. Okay, that's helpful.

<unk> and revenue more accurately because we have a more stable membership base and we have a higher returning membership so between those two things we do believe we have very good.

Line of sight into where we think things will land.

Okay, if I could slip in another one and just you said return to growth.

And I'm curious.

Timing of that what exactly are you.

I guess insinuating with that comment.

Yeah. So what we're saying there is that we absolutely have been focused on adjusted EBITDA profitability and attaining adjusted EBITDA profitability without the need for additional capital right and so that's been our focus it remains our focus and we are in striking distance of that and I feel good about that that means that because you know that has been the pri.

Andrew Toy: And just how are you thinking about star ratings and improving them going forward? Yeah, absolutely. And so one thing that I will say is that we are focused on our star rating and making sure that we are able to clearly land and execute against a three and a half star rating and then have a pathway to four. There are a couple of different things that we are able to say about our performance there. Number one is that with the two key methodologies being applied last year, one thing that did come into play is these new guardrails around star ratings. What that does is while the baseline for stars did shift significantly last year, there is also significantly more predictability now and where cut points will land.

Already we have not been focused on necessarily membership growth. During this period and I think that's appropriate I also think that that has been a good strategic move on our part because those people who really took on a lot of P. P O risk and didn't have managed those those management capabilities I think I've had seen it it would be difficult for them to manage their.

Performance because they don't have something in my Clover assistant to provide their management capabilities on that wide network now what we've been focused on a lot of things in the last couple of years maturing as a public company maturing operations Rebase lining our P. M. P. M servicing admin costs lots of maturation that we've been focused on to drive.

Andrew Toy: And I think that is advantageous to not just us but all plans in terms of having higher predictability. And that's something we're pricing into all of our star rating methodologies so that we know that we can manage against that three and a half stars and then proceed nicely towards that four star level. Second of all, I do think that when we look at star ratings, it's much harder to predict your star rating when you're growing significantly. And both in twenty-three and twenty-four, we have a more stable membership. And because of that more stable membership, we're able to anticipate things like star rating performance. These things like our met adherence denominators are more stable, and we are also able to estimate utilization and revenue more accurately because we have a more stable membership base and we have a higher returning membership. So, between those two things, we do believe we have a very good line of sight into where we think things will land.

That path to profitability and as we get all of those boxes ticked I think youre going to see US go through that adjusted EBITA zero pathway deliver profit and then start to say to ourselves we matured our platform. We've matured our operations now how do we start picking up more membership again growing top line, while still enjoying the <unk>.

<unk> that we delivered in the last couple of years.

We do have a follow up from Jason Cazorla with Citi.

Great. Thanks, I just had a couple of numbers items I want to follow up on first can you remind us of what the SG&A cost load was for the ACO reach business.

For 2023, as we think about modeling and then.

Second just if theres any prior period development inside of the 2023 MLR that 81 point too just so we can think about the right jump off point for 24. Thanks.

Andrew Toy: Okay, if I could slip in another one and just you said return to growth. And I'm curious, you know, about the timing of that. What exactly are you, I guess, insinuating with that comment?

Yeah. So I think there's a couple of different things. One is that you can see here in our full year results for S. We effectively are loaded our results for 2023 and made the adjustments around yet around SG&A there.

Andrew Toy: Yeah, so what we're saying there is that we absolutely have been focused on adjusted EBITDA profitability and attaining adjusted EBITDA profitability without the need for additional capital, right? And so that's been our focus. It remains our focus, and we are in striking distance of that. And I feel good about that. That means that because, you know, that has been the priority, we have not necessarily been focused on membership growth during this period. And I think that's appropriate.

In terms of adjusted EBITDA. So you can look at our SG&A run rate in our optimizations are going forward in our guide really saying that we're reducing those operations largely to zero in 2024. So hopefully that gives you an idea of like what that targeting and looks like of course, there are onetime costs related to exiting that program, but.

Those would've been adjusted out from the adjusted EBITDA. The other thing on the PPE dimension is is that we generally do feel like our full year MCR is a good proxy for our complete performance.

Adam Matan Ron: I also think that that has been a good strategic move on our part because those people who really took on a lot of PPO risk and didn't have managed those management capabilities, I think have seen it be difficult for them to manage their performance because they didn't have something like Clover Assistant to provide their management capabilities on that wide network. Now, we've been focused on a lot of things in the last couple of years, maturing as a public company, maturing operations, re-basing our PM PM servicing admin costs, lots of maturation that we've been focused on to drive that path to profitability. And as we get all those boxes ticked, I think you're going to see us go through that adjusted EBITDA zero pathway, deliver profit, and then start to say to ourselves, we've matured our platform, we've matured our operations.

Quarter to quarter, there are some things that flow in and out and as expected due to <unk> and Ken calculations. So normally what we say is if you look at our full year projections and our full year. Our results. Those give you a good idea of what our true performance is like because those that don't PPD effects tend to net out across the full year basis.

As a reminder to ask a question. Please press star one.

And that is star one to ask a question.

Alright, so if we have no more questions. Thank you everybody for a for asking those questions.

So hedge.

Heading heading into 'twenty 'twenty four I hope that everybody gets a sense for the increasing confidence that we have in achieving our profitability on an adjusted EBITDA basis in 2024 as well as the durability of that progress setting us up for success in future years, we've delivered favorable results.

Adam Matan Ron: Now, how do we start picking up more membership again, growing the top line while still enjoying the optimizations that we've delivered in the last couple of years? We do have a follow-up from Jason Cassorla with Citi. Great, thanks. I just had a couple of numbers items I wanted to follow up on. First, can you remind us of what the SG&A cost load was for the ACO reach business for 2023 as we think about modeling? And then second, just if there's any prior period development inside of the 2023 MLR of that 81.2, just so we can think about the right jump-off point for 24. Thanks. Yeah, so I think there are a couple of different things.

Each and every quarter this year driven by the strong unit economics of our core MA business on that PPO chassis, and our differentiated care management platform that we continue to significantly invest in so between these two things. This gives us great confidence in the trajectory of our business and our ability to.

Adam Matan Ron: One is that, as you can see in our full-year results, we have effectively loaded our results for 2023 and made the adjustments around SG&A there in terms of adjusted EBITDA. So you can look at our SG&A run rate and our optimizations going forward, and our guide really says that we're reducing those operations largely to zero in 2024. So hopefully, that gives you an idea of what that targeting looks like.

To succeed in the long term, we expect to continue to build upon this momentum in 2024 and I look forward to updating you all on even more progress in the future. So thank you all thank you.

This concludes todays <unk> fourth quarter and full year 2023 earnings call and webcast. You may disconnect. Your lines at this time have a wonderful day.

Adam Matan Ron: Of course, there are one-time costs related to exiting that program, but those would have been adjusted out from the adjusted EBITDA. The other thing on the PPE dimension is that we generally do feel like our full-year MCR is a good proxy for our overall performance. Quarter to quarter, there are some things that flow in and out, and that's expected due to, you know, IBNR and calculations. So normally, what we say is if you look at our full-year projections and our full-year results, those give you a good idea of what our true performance is like because those PPD effects tend to net out across the full year. Just a reminder, to ask a question, please press star 1, meaning that it's star one fast.

[music].

Uh huh.

[music].

Yeah.

Yeah.

Yeah.

Yeah.

Adam Matan Ron: All right, so if we have no more questions, thank you everybody for asking those questions. Heading into 2024, I hope that everybody gets a sense of the increasing confidence that we have in achieving profitability on an adjusted EBITDA basis in 2024, as well as the durability of that progress, setting us up for success in future years. We've delivered favorable results each and every quarter this year, driven by the strong unit economics of our core MA business on that PPO chassis and our differentiated care management platform, which we continue to significantly invest in. So between these two things, this gives us great confidence in the trajectory of our business and our ability to succeed in the long term. We expect to continue to build upon this momentum in 2024, and I look forward to updating you all on even more progress in the future.

Okay.

Yeah.

Hum.

[music].

Mhm.

Uh huh.

Hum.

Uh huh.

Uh huh.

Hum.

[music].

Andrew Toy: So, thank you all. Thank you. This concludes today's Clover Health fourth quarter and full year 2023 earnings call and webcast. You may disconnect your line at this time. Have a wonderful day! Go to Beadaholique.com for all of your beading supply needs! Thank you for watching. We'll see you next time. If you have a question about Jonathan Yong, it's right over here. I'm Hope K background.

Okay.

[music].

Okay.

[music].

Operator: Dad. Oh, oh, oh, oh, uh. Ahhhhhhhh, .?

Operator: Thank you for watching, and please like and support!

Okay.

[music].